These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 8858971

  • 21. Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization.
    Bradford CS, Walthers EA, Stanley DJ, Baugh MM, Moore FL.
    Gen Comp Endocrinol; 2006 May 01; 146(3):275-90. PubMed ID: 16375901
    [Abstract] [Full Text] [Related]

  • 22. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists.
    Jiang Q, Sebastian A, Archer S, Bidlack JM.
    J Pharmacol Exp Ther; 1994 Mar 01; 268(3):1107-13. PubMed ID: 7511163
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
    Negus SS, Burke TF, Medzihradsky F, Woods JH.
    J Pharmacol Exp Ther; 1993 Nov 01; 267(2):896-903. PubMed ID: 8246165
    [Abstract] [Full Text] [Related]

  • 25. Dopamine depletion produces augmented behavioral responses to a mu-, but not a delta-opioid receptor agonist in the nucleus accumbens: lack of a role for receptor upregulation.
    Churchill L, Kalivas PW.
    Synapse; 1992 May 01; 11(1):47-57. PubMed ID: 1318584
    [Abstract] [Full Text] [Related]

  • 26. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL, Janvey AJ, Bolan E, Berezowska I, Nguyen TM, Schiller PW, Pasternak GW.
    J Pharmacol Exp Ther; 2003 Aug 01; 306(2):430-6. PubMed ID: 12663687
    [Abstract] [Full Text] [Related]

  • 27. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.
    Emmerson PJ, Liu MR, Woods JH, Medzihradsky F.
    J Pharmacol Exp Ther; 1994 Dec 01; 271(3):1630-7. PubMed ID: 7996478
    [Abstract] [Full Text] [Related]

  • 28. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S, Balboni G, Guerrini R, Tomatis R, Bianchi C, Bryant SD, Cooper PS, Lazarus LH.
    J Med Chem; 1997 Sep 12; 40(19):3100-8. PubMed ID: 9301674
    [Abstract] [Full Text] [Related]

  • 29. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E, Yaksh TL.
    J Pharmacol Exp Ther; 1991 Aug 12; 258(2):544-50. PubMed ID: 1650833
    [Abstract] [Full Text] [Related]

  • 30. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
    Sterious SN, Walker EA.
    J Pharmacol Exp Ther; 2003 Jan 12; 304(1):301-9. PubMed ID: 12490605
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation.
    Chakrabarti S, Yang W, Law PY, Loh HH.
    Mol Pharmacol; 1997 Jul 12; 52(1):105-13. PubMed ID: 9224819
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Binding to mu and delta opioid sites but not kappa sites is inhibited by Fab fragments from a monoclonal antibody directed against the opioid receptor.
    Bidlack JM.
    NIDA Res Monogr; 1986 Jul 12; 75():21-4. PubMed ID: 2828974
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL, Bartlett JL, Ananthan S, Bilsky EJ.
    J Pharmacol Exp Ther; 2001 May 12; 297(2):597-605. PubMed ID: 11303048
    [Abstract] [Full Text] [Related]

  • 39. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
    Tam SW, Liu-Chen LY.
    J Pharmacol Exp Ther; 1986 Nov 12; 239(2):351-7. PubMed ID: 3021954
    [Abstract] [Full Text] [Related]

  • 40. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors.
    Hatzoglou A, Bakogeorgou E, Castanas E.
    Eur J Pharmacol; 1996 Jan 25; 296(2):199-207. PubMed ID: 8838457
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.